SUBSCRIBE
SUBSCRIBE

C4 Therapeutics

NEWS
Booming C4 Therapeutics to Move Out of Pricey Kendall Square Next Year
Business
What You Need to Know About C4 Therapeutics
January 3, 2017
 · 
6 min read
Load More
AWARDS
  • NextGen Class of 2017
JOBS
IN THE PRESS
News
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 16, 2024
 · 
2 min read
News
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 8, 2024
 · 
1 min read
Business
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 8, 2024
 · 
12 min read
Genetown
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 29, 2024
April 29, 2024
 · 
1 min read
Genetown
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 9, 2024
 · 
1 min read
Drug Development
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor
April 8, 2024
 · 
4 min read
Drug Development
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 5, 2024
 · 
2 min read
Genetown
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 4, 2024
 · 
4 min read
Business
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
 · 
13 min read
Genetown
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
January 9, 2024
 · 
10 min read
Load More